Competitive DifferentiationAlixorexton demonstrated significant improvements in wakefulness, fatigue, and cognition, which could enhance patients' quality of life and differentiate Alkermes from competitors.
Efficacy ValidationThe study helped validate ALKS2680 as an active drug in NT1 in a ~90 patient study reaching clinically meaningful and nominal stat sig on key measures of efficacy (MWT/wakefulness and Epworth sleepiness).
Safety ProfileAlixorexton is generally well-tolerated with no treatment-related safety signals observed, indicating a favorable safety profile.